Related Experiment Video
Updated: Jun 30, 2026
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
New targets for drug development in asthma.
Ian M Adcock1, Gaetano Caramori, K Fan Chung
1Airways Disease Section, National Heart and Lung Institute, Imperial College London, London, UK.
Lancet (London, England)
|September 23, 2008
Summary
Asthma affects 300 million globally, with 5-10% having severe, difficult-to-treat disease. Future therapies will target specific inflammatory pathways for personalized asthma management.
Area of Science:
- Pulmonology
- Immunology
- Pharmacology
Background:
- Asthma is a chronic airway inflammatory disease affecting 300 million worldwide, projected to increase.
- While most patients respond to inhaled corticosteroids and beta-agonists, 5-10% have severe, refractory asthma.
- Advances in understanding asthma phenotypes reveal distinct inflammatory profiles, guiding targeted therapies like anti-leukotrienes and omalizumab.
Purpose of the Study:
- To review current knowledge of asthma pathophysiology and inflammatory mechanisms.
- To discuss emerging therapeutic strategies targeting specific pathways and mediators.
- To explore the potential for personalized medicine in severe asthma treatment.
Main Methods:
- Literature review of asthma pathophysiology, phenotypes, and treatment advancements.
- Analysis of current and investigational therapeutic agents.
- Discussion of future directions in asthma research and clinical management.
Main Results:
- Recognition of distinct asthma phenotypes linked to specific inflammation types.
- Identification of novel therapeutic targets including p38 MAPK, antioxidants, IL-13, and immunoregulatory cells.
- Potential for combination therapies to overcome corticosteroid insensitivity in severe asthma.
Conclusions:
- Further research into airway inflammation mechanisms is crucial for improved asthma therapies.
- Development of targeted therapies and combination treatments holds promise for managing severe asthma.
- Personalized treatment strategies based on distinct asthma subtypes are a future goal, though a cure remains distant.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.